ArticleDiagnostic pathology2026
Clinicopathological and prognostic insights into Embryonal Tumors with Multilayered Rosettes (ETMRs).
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmbryonal tumors with multilayered rosettes (ETMRs) are rare, highly aggressive pediatric brain neoplasms characterized by early onset and dismal prognosis. This study presents a comprehensive clinicopathological and molecular analysis of ETMR cases diagnosed over a 14-year period at National Cancer Institute, Cairo University, with a focus on diagnostic features, clinical presentation, and survival outcomes.
methodsA retrospective review of 35 patients with histopathologically confirmed ETMRs was conducted. Demographic data, clinical symptoms, neuroimaging findings, histopathologic features-including rosette formation, mitotic activity, necrosis, and Ki67 proliferation index-as well as molecular analyses for C19MC amplification and LIN28A expression were evaluated. Kaplan-Meier survival curves and univariable Cox regression were used to assess prognostic associations.
resultsThe cohort comprised 17 females and 18 males, with a median age of 36 months. Common presenting symptoms included signs of raised intracranial pressure, seizures, and motor deficits. Gross total resection was achieved in 43% of patients, and 48% received adjuvant chemoradiotherapy.Histopathologic examination consistently revealed ependymoblastic rosettes (true multilayered rosettes) and high mitotic activity. LIN28A was diffusely expressed in all assessable cases. Molecular confirmation by PCR testing was done in 20 cases. The median overall survival was 19 months. Factors associated with inferior survival included incomplete surgical resection, absence of adjuvant therapy, and presence of necrosis and high mitotic index.
conclusionETMRs demonstrate consistent histological and immunohistochemical features that can guide diagnosis in resource-limited settings. Despite therapeutic advances, prognosis remains poor, underscoring the urgent need for novel therapeutic strategies. Molecular testing for C19MC amplification and LIN28A expression supports diagnostic confirmation and may hold future prognostic or therapeutic relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.